Image source: Centers for Disease Control and Prevention.
What: Shares of Advaxis (NASDAQ: ADXS), a clinical-stage biotechnology company focused on the development of cancer immunotherapies, dropped 14% in April, according to data from S&P Global Market Intelligence.